Moleculin Biotech (MBRX)
(Delayed Data from NSDQ)
$0.40 USD
-0.01 (-2.26%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $0.40 0.00 (-0.67%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MBRX 0.40 -0.01(-2.26%)
Will MBRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MBRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MBRX
Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now
MBRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy
Other News for MBRX
Moleculin Biotech (MBRX) Files to Sell 64.86 Million Common Shares
Pocket Pivot appears for MBRX after 4.6% move
Moleculin Biotech files to sell 64.86M shares of common stock by selling shareholder
Moleculin Biotech files to sell 64.86M shares of common stock for holders
Moleculin Biotech files to sell 64.86M shares of common stock for holders